Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025 - OncoCyte ( NASDAQ:OCX )
Transplant centers representing about 9% of German transplant volumes and about 2% of U.S. transplant volumes have signed on to use GraftAssure kitted research test in early launch phase FDA pre-submission process for approval of kitted clinical test is underway
| Ticker |
Sentiment |
Impact |
|
BIO
|
Neutral
|
3 %
|
|
OCX
|
Neutral
|
18 %
|
